|Assessment Status||Rapid review complete|
|Indication||For the treatment of chronic lymphocytic leukaemia (CLL)|
|Rapid review commissioned||03/01/2017|
|Rapid review completed||08/02/2017|
|Rapid review outcome||Full HTA not recommended until further evidence available|
|08/05/2018||21/06/2018||Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.|
The HSE has approved reimbursement following confidential price negotiations – December 2018.